medicina58巻3号

2021年03月発行

特集 いまさら聞けない！ 肝胆膵疾患—みなさんのギモンに答えます 肝硬変の診断と合併症に対する治療

血小板減少に対する対応

著者： 石川達¹

所属機関： ¹済生会新潟病院消化器内科

ページ範囲：P.458 - P.462

Question 1
肝硬変症例における血小板減少はなぜ起こるのですか？

参考文献

1）Seeff LB, et al.：Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol 8：877-883, 2010

2）Argo CK, Balogun RA：Blood products, volume control, and renal support in the coagulopathy of liver disease. Clin Liver Dis 13：73-85, 2009

3）高見昭良，他；日本輸血・細胞治療学会：科学的根拠に基づいた血小板製剤の使用ガイドライン：2019年改訂版．日輸血細胞治療会誌65：544-561, 2019

4）Torrance G：Splenectomy in Banti's disease, with report of a case. Ann Surg 47：41-52, 1908

5）Sugawara Y, et al：Splenectomy in patients with hepatocellular carcinoma and hypersplenism. J Am Coll Surg 190：446-450, 2000

6）Shimada M, et al：A new surgical strategy for cirrhotic patients with hepatocellular carcinoma and hypersplenism. Performing a hepatectomy after a laparoscopic splenectomy. Surg Endosc 14：127-130, 2000

7）Imura S, et al：Impact of splenectomy in patients with liver cirrhosis；Results from 18 patients in a single center experience. Hepatol Res 40：894-900, 2010

8）Styrt B：Infection associated with asplenia；Risks, mechanisms, and prevention. Am J Med 88：33-42, 1990

9）Lortan JE：Management of asplenic patients. Br J Haematol 84：566-569, 1993

10）Waghorn DJ：Overwhelming infection in asplenic patients；Current best practice preventive measures are not being followed. J Clin Pathol 54：214-218, 2001

11）Maddison FE：Embolic therapy of hypersplenism. Invest Radiol 8：280-281, 1973

12）Spigos DG, et al：Partial splenic embolization in the treatment of hypersplenism. Am J Roentgenol 132：777-782, 1979

13）Yoshida H, et al：Partial splenic embolization. Hepatol Res 38：225-233, 2008

14）Miyake Y, et al：Partial splenic embolization prior to combination therapy of interferon and ribavirin in chronic hepatitis C patients with thrombocytopenia. Hepatol Res 38：980-986, 2008

15）Ishikawa T, et al：Telaprevir-based triple therapy after partial splenic arterial embolization for chronic hepatitis C with thrombocytopenia can reduce carcinogenesis and improve hepatic function reserve. Exp Ther Med 10：1334-1338, 2015

16）Hidaka H, et al：Therapeutic benefits of partial splenic embolization for thrombocytopenia in hepatocellular carcinoma patients treated with radiofrequency ablation. Hepatol Res 39：772-778, 2009

17）Ishikawa T, et al：Concurrent partial splenic embolization with transcatheter arterial chemoembolization for hepatocellular carcinoma can maintain hepatic functional reserve. Hepatol Res 44：1056-1061, 2014

18）Ishikawa T, et al：Prevalence of Howell-Jolly bodies due to partial splenic embolization for portal hypertension. Intern Med 52：1765-1768, 2013

19）Hidaka H, et al：Lusutrombopag reduces need for platelet transfusion in patients with thrombocytopenia undergoing invasive procedures. Clin Gastroenterol Hepatol 17：1192-1200, 2019

20）Afdhal NH, et al：Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med 367：716-724, 2012

21）Ishikawa T, et al：Efficacy and safety of repeated use of lusutrombopag prior to radiofrequency ablation in patients with recurrent hepatocellular carcinoma and thrombocytopenia. Hepatol Res 49：590-593, 2019